The proportion of CGM use in people with T2D is relatively low compared to people with T1D but CGM uptake by people with T2D is increasing rapidly, with most growth in primary care, including among people with non‐insulin treated T2D.13, 14. This evidence concerns the gene INS and type 1 diabetes mellitus.